Navigation Links
Life Technologies Announces Third Quarter 2013 Results
Date:11/5/2013

ne months ended September 30, 2012, Non-GAAP earnings resulted in total revenue of $2.8 billion, gross profit of $1.8 billion with gross margin of 65.9%, operating profit of $809.8 million with operating margin of 28.9%, and an income tax provision of $199.0 million with the Non-GAAP effective tax rate of 27.8% with the above adjustments.Notes(1)

Adjust for historical portion of royalty licensing settlement of $2.8 million, and add back purchased deferred revenue of $1.4 million for the nine months ended September 30, 2013.  Add back purchased deferred revenue of $0.8 million and adjust for revenue related to a discontinued product of $0.5 million for the nine months ended September 30, 2012.(2)

Add back amortization of purchased intangibles of $213.9 million and amortization of a fair value inventory write-up of $1.5 million, offset by contingent consideration revaluation of $4.6 million for the nine months ended September 30, 2013.  Add back amortization of purchased intangibles of $219.2 million and a legal judgment of $48.5 million partially offset by $0.2 million related to the historical portion of the settlement of licensing disputes for the nine months ended September 30, 2012. (3)

Add back contingent consideration revaluation of $1.0 million and depreciation of purchase accounting property, plant, and equipment revaluation of $1.0 million for the nine months ended September 30, 2013. Add back depreciation of purchase accounting property, plant, and equipment revaluation of $2.9 million, and add back legal settlement of $11.4 million and adjust for compensation cost of $0.9 million related to the historical portion of the settlement of a licensing dispute for the nine months ended September 30, 2012. Add back business consolidation costs including restructuring and integrating acquired entities, aligning acquired and existing operations through business transformation activities and c
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. UV Flu Technologies Expands Its International Footprint
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
5. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
6. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
7. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
8. Animal Biotechnology - Technologies, Markets and Companies
9. Gene Therapy - Technologies, Markets and Companies
10. Biomarkers - Technologies, Markets and Companies
11. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... ITMN ) today announced that five abstracts from clinical ... programs related to the hepatitis C virus (HCV) have been ... European Association for the Study of the Liver (EASL, April ... to be available at www.easl.ch . ITMN-191 is ...
... David P. Wright, Co-Chair of the Alliance ... Inc., testified today before the House Labor, Health ... the critical importance of developing drugs, vaccines and ... bioterrorism and other catastrophic health emergencies. Effective medical ...
... BBK Worldwide to Better Serve Asia-Pacific Clinical Trial ... a global leader in patient recruitment for clinical ... -- Osaka, G.K., in Osaka, Japan. The company ... and medical device companies, as well as CROs ...
Cached Biology Technology:InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 2InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting 3Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Bucknell University biology professor Chris Martine has discovered and ... Lost City. Martine, who named the plant Solanum cowiei ... PhytoKeys . Martine described the plant as "gender ... male by producing pollen. "What they,re really doing ...
... Current pledges for greenhouse gas emission reductions are ... reach internationally agreed climate targets, according to new ... research teams coordinated by the International Institute for ... for Climate Impacts Research (PIK)., In the absence ...
... alcohol severely disrupts major features of brain development ... motor function, conditions typical in humans with Fetal ... the University of California, Riverside. In a ... prenatal exposure to alcohol significantly altered the expression ...
Cached Biology News:Unlikely collaboration leads to discovery of 'gender-bending' plant 2Unlikely collaboration leads to discovery of 'gender-bending' plant 3Continuing with pledge pathways to 2030 could push climate goals out of reach 2Prenatal exposure to alcohol disrupts brain circuitry 2Prenatal exposure to alcohol disrupts brain circuitry 3
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Biology Products: